top of page


Common barriers to effective clinical diagnostics

and research include:

  • Low concentration of analytes

  • Rapid degradation of analytes

  • Presence of interfering substances

  • Invasive sample collection requirements

The Nanotrap® particle technology overcomes these barriers, enabling the capture, concentration, and preservation of low abundance analytes from complex biological samples. 


A well validated technology platform with over 50 peer-reviewed publications and 14 patents to-date.

Nanotrap® particles are highly porous hydrogel particles, functionalized with chemical affinity baits which have very high affinities for different classes of analytes, such as proteins, peptides, nucleic acids, microbes, hormones, drugs-of-abuse, and extracellular vesicles.


The hydrogel structure facilitates rapid exchange with the sample for rapid binding.  Nanotrap particles are magnetically functionalized, allowing for easy recovery from the sample.  This process can be automated, enabling high-throughput sample processing.  

  • Proven sample inputs: wastewater, food wash, CSF, serum, plasma, blood, cell culture medium, transport medium, urine, oral fluid, and sweat.

  • Wide range of sample volume: 25 µL to 40 mL

  • Versatile technology platform that is amendable to magnetic functionalization and lyophilization

  • Scalable from low to high-throughput laboratory needs

The Nanotrap Technology
Workflow Integration

Workflow integration:  The Nanotrap platform can be integrated seamlessly into research and clinical workflows.  The technology has been verified on automated platforms for high-throughput sample processing and integrated into point-of-care devices.


Read what our customers are saying:

“We’re thrilled to be incorporating the Nanotrap® particle technology into our sampling practices as it will help reduce processing time and increase stability and recovery. We are particularly excited about the possibilities of future applications for this inventive technology across targets beyond COVID-19, such as opioids and other infectious diseases. This in turn will support our ability to scale our Government and Enterprise platforms to service customers including public health departments, office buildings, and universities.”


Mariana Matus, Ph.D.

Biobot Analytics


bottom of page